Name: Montu Group Pty Ltd

Submission date: 6/06/2025

1. Support business investment through corporate tax reform

1. What features of the Australian business environment have encouraged or restrained investment over the past 10 years?

The participant did not respond to this question.

2. What elements of the corporate tax system encourage and/or discourage investment and risk-taking?

The participant did not respond to this question.

3. Which parts of the corporate tax system do you find the hardest, or most time or cost-intensive to comply with? How could the compliance burden of the business/company tax system be reduced?

The participant did not respond to this question.

2. Reduce the impact of regulation on business dynamism

1. What areas of regulation do you see as enhancing business dynamism and resilience? What are the reasons for your answer?

Principles-based and risk-proportionate regulation contributes positively to business dynamism. For example, frameworks developed by AHPRA and the TGA provide clear expectations that support safe innovation in healthcare. Regulations introduced by the Australian Government in 2020 and 2021 recognised telehealth as a legitimate and enduring care modality, helping enable growth in patient-centred services. When regulators engage frequently with industry and provide transparent guidance, businesses can plan with greater confidence and invest in new models of care that meet both clinical and community needs. These characteristics are central to building long-term resilience.

2. How has your regulatory burden changed over time?

The overall regulatory landscape has become more complex, particularly for businesses operating at the intersection of digital health and clinical care. However, positive changes have included greater recognition of telehealth, pathways for new therapies, and improved regulator engagement. There has also been an increase in the time and senior leadership focus required to meet evolving compliance expectations. While this reflects growing accountability, it also highlights the importance of consistent and coordinated regulation that supports innovation without adding unnecessary administrative cost.

3. What regulations do you find time-consuming, overly complex or otherwise constraining business dynamism and resilience? What are the reasons for your answer?

Nuances in digital prescribing, dispensing, and pharmacy rules across state jurisdictions can make national service delivery more complex than necessary. For example, in NSW, all prescriptions must include the patient's date of birth (DOB). Other jurisdictions only require DOB on Schedule 8 prescriptions.

These inconsistencies increase compliance costs and create uncertainty for businesses that operate responsibly across jurisdictions. Similarly, the process of interpreting how new service models fit into existing frameworks can be slow and difficult, particularly where regulation has not kept pace with clinical or digital advances. Opportunities exist to streamline and align these rules in a way that maintains patient safety while supporting responsible innovation and investment.

4. Can you share any specific examples of where you think a regulator has done a good or bad job of understanding and reducing regulatory burden on businesses and why?